1. Home
  2. GLTO vs PSQH Comparison

GLTO vs PSQH Comparison

Compare GLTO & PSQH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$25.59

Market Cap

54.5M

Sector

Health Care

ML Signal

HOLD

Logo PSQ Holdings Inc.

PSQH

PSQ Holdings Inc.

HOLD

Current Price

$0.92

Market Cap

52.7M

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLTO
PSQH
Founded
2011
2021
Country
Denmark
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Advertising
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
54.5M
52.7M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
GLTO
PSQH
Price
$25.59
$0.92
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$41.00
$4.00
AVG Volume (30 Days)
37.9K
3.4M
Earning Date
03-18-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$27,534,522.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$47.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
196.08
52 Week Low
$2.01
$0.92
52 Week High
$38.33
$4.18

Technical Indicators

Market Signals
Indicator
GLTO
PSQH
Relative Strength Index (RSI) 48.86 30.76
Support Level $22.18 $1.00
Resistance Level $27.75 $1.33
Average True Range (ATR) 2.59 0.08
MACD -0.02 -0.00
Stochastic Oscillator 39.07 4.52

Price Performance

Historical Comparison
GLTO
PSQH

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

About PSQH PSQ Holdings Inc.

PSQ Holdings Inc operates the website and mobile application named as PublicSq. It is an app and website that connects freedom-loving Americans to high-quality businesses that share values, both online and in local communities. It has three reportable segments comprised of Marketplace; which includes a marketplace platform to access consumers that are drawn to patriotic values and the revenue is generated in the form of advertising and eCommerce transactions, and Brands segment in which through its wholly-owned brand, the company generates revenue from online sales of diapers and wipes and third financial technology which assists consumers, lenders, and retailers in offering point-of-sale financing products.

Share on Social Networks: